Centro Especialidades Médicas SRL (CEMEDIC)
Nuestra misión es garantizar y satisfacer la calidad de atención que nuestros pacientes necesitan, con el espíritu de empresa familiar que nos caracteriza. Nuestra visión es ser el mejor Centro Médico de Diagnóstico y Tratamiento del área metropolitana, teniendo como propósito cuidar a las personas en la atención primaria y ser referentes en el cuidado de la salud, haciendo que todos vivamos más saludables.Ramón Falcón 5206, CABA, Buenos Aires
Websitehttps://www.cemedic.com.ar/
Select an option
I am a doctor
I am a sponsor
Specializations
Covid-19
Cáncer de pulmón
Insuficiencia cardíaca
EPOC
Cardiovascular
Nefropatía
Our team
Medical staff
Jorge Emilio Salinas
Claudio Rodolfo Majul
Luis Alberto Pompozzi
Open studies
Cardiovascular disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) - Boehringer IngelheimSee more
Obesity
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) - Boehringer IngelheimSee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Renal disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) - Boehringer IngelheimSee more
Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy - CAMBRIA-1 - AstraZenecaSee more
Heart failure
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/SSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Inflammation
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/SSee more
